CDXS Codexis

Codexis to Participate in Upcoming Healthcare Conferences

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences.

The Stifel 2024 Healthcare Conference (New York, NY)

  • Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat

The Jefferies London Healthcare Conference (London, UK)

  • Tuesday, November 19, 2024, at 9:30 am GMT, management will participate in a fireside chat

The 15th Annual Craig-Hallum Alpha Select Conference (New York, NY)

  • Tuesday, November 19, 2024, management will host 1x1 investor meetings

The Stephens Annual Investment Conference (Nashville, TN)

  • Thursday, November 21, 2024, at 12:00 pm CT, management will participate in a fireside chat

Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, . A replay of each fireside chat will be archived for 90 days following the presentation date.

About Codexis

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .

For More Information

Investor Contact

Carrie McKim

(336) 608-9706

Media Contact

Lauren Musto

(650) 421-8205



EN
04/11/2024

Underlying

CDXSCodexis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE
Free
CDXS CODEXIS

Codexis to Participate in Piper Sandler 36th Annual Healthcare Confere...

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 11:00 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s ...

November 19, 2024 1 EN
 PRESS RELEASE
Free
CDXS CODEXIS

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Futu...

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics —Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today ...

November 14, 2024 1 EN
 PRESS RELEASE
Free
CDXS CODEXIS

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Dire...

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company’s Board of Directors. “We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “Raymond brings a deep understanding of the c...

November 12, 2024 1 EN
 PRESS RELEASE
Free
CDXS CODEXIS

Codexis TIDES Europe Presentations to Feature Next Step in Evolution o...

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics —Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today ann...

November 11, 2024 1 EN
 PRESS RELEASE
Free
CDXS CODEXIS

Codexis Announces New Employment Inducement Grants

Codexis Announces New Employment Inducement Grants REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company’s 2024...

November 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch